The University of California, San Francisco cancer of the prostate risk assessment score: A straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy

被引:593
作者
Cooperberg, MR
Pasta, DJ
Elkin, EP
Litwin, MS
Latini, DM
DuChane, J
Carroll, PR
机构
[1] Univ Calif San Francisco, Mt Zion Canc Ctr, San Francisco, CA 94115 USA
[2] Univ Calif Los Angeles, Los Angeles, CA USA
[3] TAP Pharmaceut Prod Inc, Lake Forest, IL USA
关键词
prostatic neoplasms; risk factors; prognosis; prostate-specific antigen;
D O I
10.1097/01.ju.0000158155.33890.e7
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: Multivariate prognostic instruments aim to predict risk of recurrence among patients with localized prostate cancer. We devised a novel risk assessment tool which would be a strong predictor of outcome across various levels of risk, and which could be easily applied and intuitively understood. Materials and Methods: We studied 1,439 men diagnosed between 1992 and 2001 who had undergone radical prostatectomy and were followed in the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) database, a longitudinal, community based disease registry of patients with prostate cancer. Disease recurrence was defined as prostate specific antigen (PSA) 0.2 ng/ml or greater on 2 consecutive occasions following prostatectomy or a second cancer treatment more than 6 months after surgery. The University of California, San Francisco-Cancer of the Prostate Risk Assessment (UCSF-CAPRA) score was developed using preoperative PSA, Gleason score, clinical T stage, biopsy results and age. The index was developed and validated using Cox proportional hazards and life table analyses. Results: A total of 210 patients (15%) had recurrence, 145 by PSA criteria and 65 by second treatment. Based on the results of the Cox analysis, points were assigned based on PSA (0 to 4 points), Gleason score (0 to 3), T stage (0 to 1), age (0 to 1) and percent of biopsy positive cores (0 to 1). The UCSF-CAPRA score range is 0 to 10, with roughly double the risk of recurrence for each 2-point increase in score. Recurrence-free survival at 5 years ranged from 85% for a UCSF-CAPRA score of 0 to 1 (95% CI 73%-92%) to 8% for a score of 7 to 10 (95% Cl 0%-28%). The concordance index for the UCSF-CAPRA score was 0.66. Conclusions: The UCSF-CAPRA score is a straightforward yet powerful preoperative risk assessment tool. It must be externally validated in future studies.
引用
收藏
页码:1938 / 1942
页数:5
相关论文
共 20 条
  • [11] Cancer statistics, 2004
    Jemal, A
    Tiwari, RC
    Murray, T
    Ghafoor, A
    Samuels, A
    Ward, E
    Feuer, EJ
    Thun, MJ
    [J]. CA-A CANCER JOURNAL FOR CLINICIANS, 2004, 54 (01) : 8 - 29
  • [12] A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer
    Kattan, MW
    Eastham, JA
    Stapleton, AMF
    Wheeler, TM
    Scardino, PT
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (10): : 766 - 771
  • [13] Long-term cancer control of radical prostatectomy in men younger than 50 years of age: Update 2003
    Khan, MA
    Han, M
    Partin, AW
    Epstein, JI
    Walsh, PC
    [J]. UROLOGY, 2003, 62 (01) : 86 - 91
  • [14] The CaPSURE database: A methodology for clinical practice and research in prostate cancer
    Lubeck, DP
    Litwin, MS
    Henning, JM
    Stier, DM
    Mazonson, P
    Fisk, R
    Carroll, PR
    [J]. UROLOGY, 1996, 48 (05) : 773 - 777
  • [15] Ability of 2 pretreatment risk assessment methods to predict prostate cancer recurrence after radical prostatectomy: Data from CaPSURE
    Mitchell, JA
    Cooperberg, MR
    Elkin, EP
    Lubeck, DP
    Mehta, SS
    Kane, CJ
    Carroll, PR
    [J]. JOURNAL OF UROLOGY, 2005, 173 (04) : 1126 - 1131
  • [16] Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium
    Partin, AW
    Mangold, LA
    Lamm, DM
    Walsh, PC
    Epstein, JI
    Pearson, JD
    [J]. UROLOGY, 2001, 58 (06) : 843 - 848
  • [17] Positive fraction of systematic biopsies predicts risk of relapse after radical prostatectomy
    Presti, JC
    Shinohara, K
    Bacchetti, P
    Tigrani, V
    Bhargava, V
    [J]. UROLOGY, 1998, 52 (06) : 1079 - 1084
  • [18] Ross PL, 2001, J UROLOGY, V165, P1562, DOI 10.1016/S0022-5347(05)66349-5
  • [19] Prostate cancer in men age 50 years or younger: A review of the Department of Defense Center for Prostate Disease Research multicenter prostate cancer database
    Smith, CV
    Bauer, JJ
    Connelly, RR
    Seay, T
    Kane, C
    Foley, J
    Thrasher, JB
    Kusuda, L
    Moul, JW
    [J]. JOURNAL OF UROLOGY, 2000, 164 (06) : 1964 - 1967
  • [20] Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer
    Wei, JT
    Dunn, RL
    Sandler, HM
    McLaughlin, PW
    Montie, JE
    Litwin, MS
    Nyquist, L
    Sanda, MG
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (02) : 557 - 566